PEI first province to offer GARDASIL® to boys in school

Canadian parents support vaccinating boys in publicly funded programs

B-roll available at:  http://cnw.pathfireondemand.com/viewpackage.action?packageid=706

KIRKLAND, QC, April 18, 2013 /CNW Telbec/ - Today, Prince Edward Island became the first province in Canada to extend its publicly funded school-based HPV vaccination program to boys. The program will use GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine], the only HPV vaccine indicated and recommended for boys and men.

In 2007, The National Advisory Committee on Immunization (NACI) recommended the quadrivalent HPV vaccine to protect Canadian girls and women aged 9 to 26 against a broad spectrum of HPV-related diseases. In 2012, NACI updated and strengthened its statement related to the use of HPV vaccines and recommended the use of the quadrivalent HPV vaccine in males between 9 to 26 years of age.1

"PEI was one of the first provinces to follow NACI's recommendations by introducing school-based HPV vaccination programs to girls in 2007. PEI's decision to include boys is an important milestone in protecting both males and females against the diseases that can result from HPV infection such as genital warts and anal-genital cancers," said Dr. Mauricio Ede, Medical Director, Medical Affairs at Merck Canada. "Both males and females contribute to the spread of HPV and both develop diseases as a result of HPV infection."

More recently, The Canadian Medical Association adopted a resolution that calls for public funding to vaccinate both girls and boys for human papillomavirus.2

A national survey conducted in March 2011 by Ipsos Reid3, commissioned by Merck, showed that:

  • 85% of parents of males would allow their son to get vaccinated against HPV if it was offered through a publicly-funded program at his school
  • 88% of parents support the assertion that boys should be vaccinated against HPV in the same program as girls
  • 91% of parents agree that vaccinating both boys and girls against HPV would provide greater protection than vaccinating girls alone


Australia, a country to which Canada is often compared, extended its national school-based HPV vaccination program to boys aged 12-13, earlier this year. It includes a catch-up program for 14 to 15 year-olds until the end of the 2014 school year.4

About Merck
Today's Merck is a global healthcare leader working to help the world be well.  Merck is known as MSD outside the United States and Canada. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information about our operations in Canada, visit www.merck.ca.

Forward Looking Statement

This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2011 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

The news release is available at www.cnw.ca.

____________________________

1 Public Health Agency of Canada Web site. Accessed at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php

2 The Canadian Medical Association Web site.  Accessed at: http://www.cma.ca/multimedia/CMA/Content_Images/Inside_cma/Annual_Meeting/2012/resolutions/2012GC-Resolutions_en.pdf.  See pg 4 resolution 47.

3 Ipsos Reid factum issued on January 19, 2012. Accessed at: http://www.newswire.ca/en/story/907763/nine-in-ten-88-canadian-parents-support-vaccinating-boys-against-hpv-through-public-program-at-school

4 Australian Government, Department of Health and Ageing Web site. Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv


SOURCE: Merck Canada Inc.

For further information:

Media Contacts:

Sheila Murphy
Merck
514-428-2748

Quebec
Roch Landriault
NATIONAL Public Relations
514-843-2345

Alberta
Dan Brennan
NATIONAL Public Relations
403-690-4556